• About us
• Contact

Advertisement

Organisation › Details

OrbiMed (Group)

OrbiMed is a leading healthcare investment firm, with approximately $19 billion in assets under management. OrbiMed invests globally across the healthcare industry through a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed’s team of over 100 professionals is based in New York City, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya and other key global markets. *

 

	Start	1989-01-01 established
	Industry	private equity
	Industry 2	LIFE SCIENCES
	Person	Gordon, Carl L. (OrbiMed Advisors 201509 Partner)
	Person 2	Zaks, Tal (OrbiMed 202111– Venture Partner before Moderna + Sanofi + SGK)
	Region	New York, NY
	Country	United States (USA)
	Street	601 Lexington Avenue 54th Floor
	City	10022 New York, NY
	Tel	+1-212-739-6400
		Address record changed: 2021-12-06
Basic data	Employees	D: 101 to 500 (2023-10-24)
	Currency	USD
	Annual sales	17,000,000,000 (assets under management (2023) 2023-10-24)
		* Document for »About Section«: Nerre Therapeutics Ltd.. (7/7/21). "Press Release: Nerre Therapeutics Raises £20 Million in a Series B2 Financing Round". Stevenage.
		Record changed: 2023-12-08

Advertisement

More documents for OrbiMed (Group)

• [1] OrbiMed Advisors LLC. (10/24/23). "Press Release: OrbiMed Raises $4.3 Billion Across Private Investment Funds". New York, NY....
• [2] Corteria Pharmaceuticals SAS. (9/7/23). "Press Release: Corteria Pharmaceuticals Announces a €65M ($71M) Financing to Advance Transformational Medicines in Cardiovascular Diseases". Paris....
• [3] OrbiMed Advisors LLC. (5/3/23). "Press Release: OrbiMed Expands to Europe, Opens London Office". New York, NY....
• [4] Upstream Bio (US). (6/2/22). "Press Release: Upstream Bio Launches with $200M Series A Financing to Advance Novel Therapeutics for Allergic and Inflammatory Diseases". Waltham, MA....
• [5] Gennao Bio. (5/10/22). "Press Release: Gennao Bio Closes $40 Million Series A Financing to Develop Pipeline of Targeted Nucleic Acid Therapeutics". New Haven, CT....
• [6] Alterome Therapeutics, Inc.. (1/19/22). "Press Release: Alterome Therapeutics Launches with $64M Series A Financing". San Diego, CA....
• [7] Odyssey Therapeutics, Inc.. (12/7/21). "Press Release: Odyssey Therapeutics Announces $218 Million Series A Financing to Advance Next Generation Inflammation and Oncology Medicines". Boston, MA....
• [8] OrbiMed Advisors LLC. (11/1/21). "Press Release: Dr. Tal Zaks and Dr. Sheila Gujrathi Join OrbiMed". New York, NY....
• [9] Gibbs, Matthew [CipherBio = SVB]. (9/30/20). "News: Blog – Biotech Funding – The Tale of Three Regions. 2020 YTD in Numbers – the US, Europe and Asia"....
• [10] ReCode Therapeutics, Inc.. (3/26/20). "Press Release: ReCode Therapeutics Raises $80 Million in Oversubscribed Series A Financing". Menlo Park, CA & Dallas, TX....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.